Latest VolitionRX Limited Stories
The pilot study is designed to assess whether VolitionRx's NuQ® assays could be used as an initial screening tool for ovarian cancer NAMUR, Belgium, Jan.
Marks Fourth Cancer Type Detected by VolitionRx's Proprietary Nucleosomics® Platform NAMUR, Belgium, Jan.
Confirmatory study will assess VolitionRx's proprietary Nucleosomics® platform for non-invasive diagnosis of lung cancer as part of larger ongoing, prospective clinical trial NAMUR, Belgium,
Pilot study demonstrates that NuQ(R) tests able to detect lung cancer in 85% of patients using sputum and 76% using blood NAMUR, Belgium, Nov.
Study will assess VolitionRx's proprietary Nucleosomics® platform for non-invasive diagnosis of endometriosis NAMUR, Belgium, Nov.
NAMUR, Belgium, Nov.
Corporate social responsibility initiative supports commitment to long-term quality of life for cancer survivors NAMUR, Belgium, Oct.
Study will assess ability of VolitionRx NuQ® to distinguish between aggressive anaplastic prostate cancer and typical castration-resistant prostate cancer (CRPC) NAMUR, Belgium, Oct.
CEO to Present Data Analysis of Colorectal Cancer Pilot Study of Approximately 1,000 Subjects NAMUR, Belgium, Sept.
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial NAMUR, Belgium, Aug.
- A hairdresser.